ANDA 40074, held by Bausch & Lomb. Proparacaine Hydrochloride.
As of Nov 22, 2026, ANDA 40074 (Proparacaine Hydrochloride), held by Bausch & Lomb, was first approved by FDA on Sep 29, 1995, with 11 approved supplements and 0 published complete response letters.
INDICATIONS AND USAGE Proparacaine hydrochloride ophthalmic solution is indicated for procedures in which a topical ophthalmic anesthetic is indicated; corneal anesthesia of short duration, e.g. tonometry, gonioscopy, removal of corneal foreign bodies and for short corneal and conjunctival procedures.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 29, 1995 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Proparacaine Hydrochloride0.5% · solution/drops;ophthalmic | Proparacaine Hydrochloride | Rx |
| Nov 27, 2001 | Supplement 11Manufacturing | Approved | None posted |
| Mar 7, 2001 | Supplement 10Manufacturing | Approved | None posted |
| Oct 5, 2000 | Supplement 9Manufacturing | Approved | None posted |
| Jun 27, 2000 | Supplement 8Manufacturing | Approved | None posted |
| May 18, 2000 | Supplement 5Manufacturing | Approved | None posted |
| May 15, 2000 | Supplement 7Manufacturing | Approved | None posted |
| Apr 28, 2000 | Supplement 6Manufacturing | Approved | None posted |
| Jun 7, 1999 | Supplement 4Manufacturing | Approved | None posted |
| Nov 19, 1998 | Supplement 3Manufacturing | Approved | None posted |
| Jul 23, 1998 | Supplement 1Labeling | Approved | None posted |
| Jul 23, 1998 | Supplement 2Manufacturing | Approved | None posted |
| Sep 29, 1995 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. “What FDA's review says” is read by a model (Claude Haiku) from FDA's summary review PDF; a field is shown only if its numbers appear in the review, and each section links the review. Drugs@FDA and FDA complete response letters